$BDSX
BIODESIX INC

2022 Q1 Form 10-K Financial Statement

#000095017022003495 Filed on March 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $6.548M $7.224M $54.51M
YoY Change -77.32% -73.27% 19.64%
Cost Of Revenue $3.235M $2.493M $30.52M
YoY Change -82.24% -82.98% 38.72%
Gross Profit $3.313M $4.731M $23.99M
YoY Change -68.89% -61.79% 1.82%
Gross Profit Margin 50.6% 65.49% 44.01%
Selling, General & Admin $14.49M $13.56M $50.52M
YoY Change 21.46% 12.42% 44.93%
% of Gross Profit 437.28% 286.58% 210.59%
Research & Development $3.206M $2.852M $12.79M
YoY Change -3.46% -8.3% 18.22%
% of Gross Profit 96.77% 60.28% 53.31%
Depreciation & Amortization $400.0K $855.0K $3.178M
YoY Change 33.33% 17.12% 9.59%
% of Gross Profit 12.07% 18.07% 13.25%
Operating Expenses $21.01M $16.41M $95.45M
YoY Change -39.01% 8.17% 39.36%
Operating Profit -$14.46M -$11.68M -$40.94M
YoY Change 159.02% 318.6% 78.51%
Interest Expense $1.137M -$1.496M $4.508M
YoY Change 74.65% 116.81% -40.72%
% of Operating Profit
Other Income/Expense, Net -$1.125M -$10.00K -$2.219M
YoY Change -18.36% -99.16% -73.63%
Pretax Income -$15.59M -$13.28M -$43.16M
YoY Change 123.94% 193.2% 37.67%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.59M -$13.28M -$43.16M
YoY Change 123.9% 193.2% 37.67%
Net Earnings / Revenue -238.03% -183.86% -79.18%
Basic Earnings Per Share -$0.50 -$1.58
Diluted Earnings Per Share -$501.6K -$490.9K -$1.577M
COMMON SHARES
Basic Shares Outstanding 31.31M 27.37M
Diluted Shares Outstanding 31.07M 27.37M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.43M $32.71M $32.71M
YoY Change -70.29% -47.32% -47.32%
Cash & Equivalents $16.40M $32.71M $32.71M
Short-Term Investments
Other Short-Term Assets $7.032M $7.245M $7.245M
YoY Change -6.24% -16.82% -16.72%
Inventory
Prepaid Expenses
Receivables $3.774M $3.656M $3.656M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $27.23M $43.61M $43.61M
YoY Change -66.46% -49.37% -49.35%
LONG-TERM ASSETS
Property, Plant & Equipment $4.028M $4.179M $4.179M
YoY Change 18.93% 31.5% 30.59%
Goodwill $15.03M $15.03M
YoY Change 0.0%
Intangibles $11.13M $11.62M
YoY Change -13.18% -12.39%
Long-Term Investments
YoY Change
Other Assets $2.009M $1.657M $1.657M
YoY Change -33.03% -52.12% -52.66%
Total Long-Term Assets $34.42M $32.48M $32.48M
YoY Change 0.34% -7.0% -7.19%
TOTAL ASSETS
Total Short-Term Assets $27.23M $43.61M $43.61M
Total Long-Term Assets $34.42M $32.48M $32.48M
Total Assets $61.65M $76.10M $76.10M
YoY Change -46.62% -37.15% -37.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.120M $1.662M $1.662M
YoY Change -42.7% -81.46% -81.53%
Accrued Expenses $6.173M $7.665M $4.899M
YoY Change -15.0% -1.59% 4.23%
Deferred Revenue $2.500M $1.900M
YoY Change 4.17% -45.71%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $51.00K $19.00K $19.00K
YoY Change -98.11% -99.84% -99.84%
Total Short-Term Liabilities $29.81M $28.96M $28.96M
YoY Change 84.89% -9.85% -9.78%
LONG-TERM LIABILITIES
Long-Term Debt $10.06M $9.993M $9.993M
YoY Change -66.82% -37.15% -37.15%
Other Long-Term Liabilities $615.0K $1.389M $17.42M
YoY Change -63.54% -27.69% -45.4%
Total Long-Term Liabilities $24.06M $27.41M $27.41M
YoY Change -61.77% -42.63% -42.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.81M $28.96M $28.96M
Total Long-Term Liabilities $24.06M $27.41M $27.41M
Total Liabilities $53.87M $56.37M $56.37M
YoY Change -31.86% -29.45% -29.45%
SHAREHOLDERS EQUITY
Retained Earnings -$317.6M -$302.0M
YoY Change 19.48% 16.68%
Common Stock $32.00K $31.00K
YoY Change 18.52% 14.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.781M $19.73M $19.73M
YoY Change
Total Liabilities & Shareholders Equity $61.65M $76.10M $76.10M
YoY Change -46.62% -37.15% -37.16%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$15.59M -$13.28M -$43.16M
YoY Change 123.9% 193.2% 37.67%
Depreciation, Depletion And Amortization $400.0K $855.0K $3.178M
YoY Change 33.33% 17.12% 9.59%
Cash From Operating Activities -$13.10M -$10.20M -$28.22M
YoY Change 15.65% 16.4% 32.09%
INVESTING ACTIVITIES
Capital Expenditures $262.0K -$641.0K $2.241M
YoY Change -43.78% 16.55% 15.22%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$352.0K -$641.0K -$2.547M
YoY Change -31.78% 16.55% -12.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.599M $16.34M
YoY Change
Debt Paid & Issued, Net $11.00K $45.43M
YoY Change -99.96%
Cash From Financing Activities -2.834M -4.363M 1.262M
YoY Change -157.24% -106.71% -98.44%
NET CHANGE
Cash From Operating Activities -13.10M -10.20M -28.22M
Cash From Investing Activities -352.0K -641.0K -2.547M
Cash From Financing Activities -2.834M -4.363M 1.262M
Net Change In Cash -16.29M -15.20M -29.51M
YoY Change 136.32% -127.26% -151.92%
FREE CASH FLOW
Cash From Operating Activities -$13.10M -$10.20M -$28.22M
Capital Expenditures $262.0K -$641.0K $2.241M
Free Cash Flow -$13.36M -$9.556M -$30.46M
YoY Change 13.31% 16.39% 30.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiability
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001439725
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39659
CY2021 dei Entity Registrant Name
EntityRegistrantName
Biodesix, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3986492
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2970 Wilderness Place
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
CY2021 dei City Area Code
CityAreaCode
303
CY2021 dei Local Phone Number
LocalPhoneNumber
417-0500
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
BDSX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
Yes
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
196500000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31307853
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
Denver, CO
CY2021 dei Auditor Firm
AuditorFirmId
185
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32712000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62126000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
158000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
180000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3656000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15304000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
7245000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8710000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26561504
CY2021Q4 us-gaap Assets Current
AssetsCurrent
43613000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
86140000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4179000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3178000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11617000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13260000
CY2021Q4 us-gaap Goodwill
Goodwill
15031000
CY2020Q4 us-gaap Goodwill
Goodwill
15031000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1657000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3461000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
32484000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
34930000
CY2021Q4 us-gaap Assets
Assets
76097000
CY2020Q4 us-gaap Assets
Assets
121070000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1662000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8964000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7665000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7789000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1850000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3532000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
17764000
CY2021Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
19000
CY2020Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
11840000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28960000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32125000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9993000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15926000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
16028000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
29932000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1389000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1921000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
27410000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
47779000
CY2021Q4 us-gaap Liabilities
Liabilities
56370000
CY2020Q4 us-gaap Liabilities
Liabilities
79904000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Capital Units Deductions From Total Cost To Investors
CapitalUnitsDeductionsFromTotalCostToInvestors
5040000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30789649
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30789649
CY2020Q4 us-gaap Capital Units Total Cost To Investors
CapitalUnitsTotalCostToInvestors
3203000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
63757000
CY2020 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
21998000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
193959000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26561504
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
321669000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
299953000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301973000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258814000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19727000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41166000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76097000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
121070000
CY2021 us-gaap Revenues
Revenues
54506000
CY2020 us-gaap Revenues
Revenues
45557000
CY2021 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
30518000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12789000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10818000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50517000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34857000
CY2021 bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
1622000
CY2020 bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
818000
CY2021 us-gaap Operating Expenses
OperatingExpenses
95446000
CY2020 us-gaap Operating Expenses
OperatingExpenses
68491000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-40940000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-22934000
CY2021 us-gaap Interest Expense
InterestExpense
4508000
CY2020 us-gaap Interest Expense
InterestExpense
7604000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1252000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2298000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
9000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
440000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2219000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8416000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43159000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-31350000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.58
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.48
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27365000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4838000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-225139000
CY2020 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
26616000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
8274000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1340000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3709000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-31350000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41166000
CY2021Q4 us-gaap Capital Units Deductions From Total Cost To Investors
CapitalUnitsDeductionsFromTotalCostToInvestors
664000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15679000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
328000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
769000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4944000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43159000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19727000
CY2021 us-gaap Profit Loss
ProfitLoss
-43159000
CY2020 us-gaap Profit Loss
ProfitLoss
-31350000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3178000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2903000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4389000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2298000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4944000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3709000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1252000
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1622000
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
818000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
193000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
296000
CY2021 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
2706000
CY2020 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
1418000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11454000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10308000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1369000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
6588000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-875000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
1808000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7425000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11654000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1682000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2249000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28223000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21366000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2241000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1945000
CY2021 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
306000
CY2020 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
232000
CY2020 bdsx Payments To Acquire Oncimmune
PaymentsToAcquireOncimmune
750000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2547000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2927000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
72000000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16343000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5468000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32798000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62306000
CY2020 bdsx Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
193959000
CY2021 bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
328000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
769000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1340000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
12955000
CY2021 bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
30078000
CY2020 bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
3085000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
45428000
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
164000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
664000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
8243000
CY2020 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-6000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1262000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
81131000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29508000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
56838000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62306000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
26616000
CY2020 bdsx Reclassification Of Put Option Liability To Additional Paid In Capital
ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital
6650000
CY2020 bdsx Value Of Put Option Recorded At Issuance Of Convertible Notes Payable
ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable
3389000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1676000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1844000
CY2020 bdsx Reclassification Of Warrant Liability To Additional Paid In Capital
ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital
1624000
CY2021 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
15000
CY2021 bdsx Number Of Cancer Test
NumberOfCancerTest
5
CY2021 bdsx Number Of Commercial Blood Based Test
NumberOfCommercialBloodBasedTest
2
CY2021 bdsx Number Of Sars Co V2 Test
NumberOfSARSCoV2Test
3
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32700000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Substantially all of the Company’s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2021 and 2020, see Note 11 – </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1500000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1500000
CY2020Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
5188000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13260000
CY2020Q4 bdsx Put Option Liability Current
PutOptionLiabilityCurrent
3400000
CY2021Q4 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
CY2021Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
300000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1300000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10928000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9902000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6749000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6724000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4179000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3178000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18755000
CY2021Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
7138000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11617000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18448000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1950000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2064000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1975000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1969000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1959000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1954000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1941000
CY2021Q4 bdsx Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter
1719000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11517000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4029000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3975000
CY2021Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
870000
CY2020Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
715000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2766000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3099000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7665000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7789000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
313000
CY2021Q4 us-gaap Notes Payable
NotesPayable
10012000
CY2020Q4 us-gaap Notes Payable
NotesPayable
27766000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
19000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11840000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9993000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15926000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
63000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
19000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
15000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4017000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4818000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
1206000
CY2021Q4 bdsx Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter
0
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
10075000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holder of each share of common stock is entitled to one vote per share.
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).
CY2021 us-gaap Revenues
Revenues
54506000
CY2020 us-gaap Revenues
Revenues
45557000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3500000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000.0
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1900000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4944000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3709000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2321000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.82
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42580000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1190
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.87
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
225
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.22
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
408
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.51
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2878000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6288000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1428
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.02
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3849000
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M23D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.685
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.770
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0079
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0034
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43159000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-31350000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27365000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4838000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.58
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.48
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3535000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2677000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.01
CY2021 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.01
CY2020 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.06
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.26
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.16
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
61874000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
53128000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3372000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2860000
CY2021Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
554000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
215000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
279000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1977000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
865000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1618000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1406000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
69610000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
58538000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67457000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56083000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2153000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2455000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2153000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2455000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2153000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2455000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
267100000
CY2021Q4 bdsx Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration
DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
4200000
CY2021 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
expire beginning in 2026
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Explanation Of Change
ValuationAllowanceDeferredTaxAssetExplanationOfChange
Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.
CY2021 bdsx Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets
PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
1
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11400000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7000000.0
CY2020Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
715000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
128000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
106000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
609000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
843000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
715000
CY2021 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1200000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
775000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
149000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
9000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
937000

Files In Submission

Name View Source Status
0000950170-22-003495-index-headers.html Edgar Link pending
0000950170-22-003495-index.html Edgar Link pending
0000950170-22-003495.txt Edgar Link pending
0000950170-22-003495-xbrl.zip Edgar Link pending
bdsx-20211231.htm Edgar Link pending
bdsx-20211231.xsd Edgar Link pending
bdsx-20211231_cal.xml Edgar Link unprocessable
bdsx-20211231_def.xml Edgar Link unprocessable
bdsx-20211231_htm.xml Edgar Link completed
bdsx-20211231_lab.xml Edgar Link unprocessable
bdsx-20211231_pre.xml Edgar Link unprocessable
bdsx-ex10_132.htm Edgar Link pending
bdsx-ex23_1.htm Edgar Link pending
bdsx-ex31_1.htm Edgar Link pending
bdsx-ex31_2.htm Edgar Link pending
bdsx-ex32_1.htm Edgar Link pending
bdsx-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img33530786_0.jpg Edgar Link pending
img33530786_1.jpg Edgar Link pending
img33530786_2.jpg Edgar Link pending
img33530786_3.jpg Edgar Link pending
img33530786_4.jpg Edgar Link pending
img33530786_5.jpg Edgar Link pending
img33530786_6.jpg Edgar Link pending
img33530786_7.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending